Search research articles
Contact Us
Filters
Showing results (1-10 of 27) with videos related to
Page
of 3
Sort By:
Malaria Journal
|
October 13, 2009
Understanding the pharmacokinetics of Coartem
Abdoulaye Djimdé, Gilbert Lefèvre
Journal of Pharmaceutical Sciences
|
May 24, 2016
Pharmacokinetic Modeling to Simulate the Concentration-Time Profiles After Dermal Application of Rivastigmine Patch
Sachiko Nozaki, Masayuki Yamaguchi, Gilbert Lefèvre
Annals of the New York Academy of Sciences
|
March 26, 2011
Novartis Malaria Initiative: best practice example of pharmaceutical industry's engagement in the fight against malaria
Gilbert Lefèvre, Anne Claire Marrast, Heiner Grueninger
The American Journal of Tropical Medicine and Hygiene
|
July 26, 2002
Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants
Margaretha Bindschedler, Gilbert Lefèvre, Peter Degen, et al.
Drugs & Aging
|
September 30, 2016
Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer's Disease
Gilbert Lefèvre, Francesca Callegari, Sandro Gsteiger, et al.
Neurology
|
July 31, 2007
Pharmacokinetic rationale for the rivastigmine patch
Jeffrey Cummings, Gilbert Lefèvre, Gary Small, et al.
British Journal of Clinical Pharmacology
|
November 26, 2002
Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects
Gilbert Lefèvre, Polly Carpenter, Claire Souppart, et al.
Current Medical Research and Opinion
|
November 16, 2007
Rivastigmine exposure provided by a transdermal patch versus capsules
François Mercier, Gilbert Lefèvre, Hsun-Lun Aaron Huang, et al.
Clinical Drug Investigation
|
May 16, 2008
Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study
Joshua Shua-Haim, Juanita Smith, Franck Picard, et al.
Antimicrobial Agents and Chemotherapy
|
April 8, 2015
Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine
Daniel S Stein, Jay Prakash Jain, Michael Kangas, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 27) with videos related to
Sort By:
Page
of 3
Malaria Journal
|
October 13, 2009
Understanding the pharmacokinetics of Coartem
Abdoulaye Djimdé, Gilbert Lefèvre
Journal of Pharmaceutical Sciences
|
May 24, 2016
Pharmacokinetic Modeling to Simulate the Concentration-Time Profiles After Dermal Application of Rivastigmine Patch
Sachiko Nozaki, Masayuki Yamaguchi, Gilbert Lefèvre
Annals of the New York Academy of Sciences
|
March 26, 2011
Novartis Malaria Initiative: best practice example of pharmaceutical industry's engagement in the fight against malaria
Gilbert Lefèvre, Anne Claire Marrast, Heiner Grueninger
The American Journal of Tropical Medicine and Hygiene
|
July 26, 2002
Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants
Margaretha Bindschedler, Gilbert Lefèvre, Peter Degen, et al.
Drugs & Aging
|
September 30, 2016
Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer's Disease
Gilbert Lefèvre, Francesca Callegari, Sandro Gsteiger, et al.
Neurology
|
July 31, 2007
Pharmacokinetic rationale for the rivastigmine patch
Jeffrey Cummings, Gilbert Lefèvre, Gary Small, et al.
British Journal of Clinical Pharmacology
|
November 26, 2002
Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects
Gilbert Lefèvre, Polly Carpenter, Claire Souppart, et al.
Current Medical Research and Opinion
|
November 16, 2007
Rivastigmine exposure provided by a transdermal patch versus capsules
François Mercier, Gilbert Lefèvre, Hsun-Lun Aaron Huang, et al.
Clinical Drug Investigation
|
May 16, 2008
Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study
Joshua Shua-Haim, Juanita Smith, Franck Picard, et al.
Antimicrobial Agents and Chemotherapy
|
April 8, 2015
Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine
Daniel S Stein, Jay Prakash Jain, Michael Kangas, et al.
Page
of 3